Grown Rogue International (GRUSF) Net Margin (2009 - 2026)

Grown Rogue International (GRUSF) posted quarterly Net Margin of 1.09% for Q1 2026, down 102.77% quarter-over-quarter from 39.35% in Q4 2025.

Grown Rogue International (GRUSF) Net Margin (2009 - 2026) Analysis & Trends

Grown Rogue International's Net Margin history runs 17 years deep, the most recent figure standing at 1.09% for Q1 2026.

In Q1 2026, Net Margin changed N/A year-over-year to 1.09%; the TTM figure through Mar 2026 stood at 0.0% (up 1393.0% YoY), while the FY2025 annual figure was 1.4%, down 45.0% from the prior year.
Net Margin for Q1 2026 stood at 1.09%, down from 39.35% in the prior quarter.
The five-year high for Net Margin was 50.31% in Q3 2025, with the low at 99.62% in Q2 2024.
The 5-year median for Net Margin is 1.67% (2023), against an average of 0.5%.
The sharpest annual moves came in 2022 and 2023: Net Margin surged 9109 bps in 2022, then soared 3190 bps in 2023.
Grown Rogue International's Net Margin stood at 11.33% in 2022, then soared by 263 bps to 18.48% in 2023, then tumbled by 162 bps to 11.42% in 2024, then jumped by 445 bps to 39.35% in 2025, then plunged by 103 bps to 1.09% in 2026.
Business Quant data shows GRUSF's Net Margin at 1.09% in Q1 2026, 39.35% in Q4 2025, and 50.31% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-13.91%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	9.28%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	42.51%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Grown Rogue International	110.47 Mn	98.93 Mn	5.37 Mn	-13.14%

Download Data